Aquestive Therapeutics (Aquestive Therapeutics) Cash-to-Debt : 0.72 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aquestive Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.72.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Aquestive Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Aquestive Therapeutics's Cash-to-Debt or its related term are showing as below:

AQST' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24 Med: 0.61 Max: 1.28
Current: 0.72

During the past 8 years, Aquestive Therapeutics's highest Cash to Debt Ratio was 1.28. The lowest was 0.24. And the median was 0.61.

AQST's Cash-to-Debt is ranked worse than
55.63% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs AQST: 0.72

Aquestive Therapeutics Cash-to-Debt Historical Data

The historical data trend for Aquestive Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aquestive Therapeutics Cash-to-Debt Chart

Aquestive Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.82

0.79

0.50

0.47

0.72

Aquestive Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.47	0.56	0.50	0.55	0.72

Competitive Comparison of Aquestive Therapeutics's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aquestive Therapeutics's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Aquestive Therapeutics's Cash-to-Debt falls into.

Aquestive Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Aquestive Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	23.872	/	(0.412	+	32.907)
	=	0.72

Aquestive Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	23.872	/	(0.412	+	32.907)
	=	0.72

Aquestive Therapeutics (NAS:AQST) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Aquestive Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Technology Drive, Warren, NJ, USA, 07059

Website

https://www.aquestive.com

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Executives

Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki	officer: SVP, Research & Development	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung	officer: SVP, Operations	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt	officer: Chief Medical Officer	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd	officer: SVP-Operations/Value Delivery	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender	officer: SVP, General Counsel	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber	officer: SVP-Chief Strategy/Dev Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel	director, officer: Chief Innovation/Tech Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr	officer: Interim CFO
John T. Maxwell	officer: SVP-Chief Financial Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall	director, officer: President and CEO	30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta	director	C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154